Physician profile
Halie Hall
NPI 1891406138
$4,458.03
in general payments reported to CMS, 2019-2025
40 companies · $2,715 in 2025
The $2,715 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $226 · 2024: $1,517 · 2025: $2,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,168 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,168.04 |
| Education | $289.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $507.25 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Janssen Biotech, INC. | $461.81 | 2024-2025 | Darzalex, Talvey, Erleada |
| Pfizer INC. | $394.61 | 2024-2025 | |
| Abbvie INC. | $348.04 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $338.47 | 2024-2025 | Enhertu, Calquence, Lynparza |
| Daiichi Sankyo INC. | $266.24 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Novartis Pharmaceuticals Corporation | $258.53 | 2023-2025 | |
| Array Biopharma INC | $148.77 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Tersera Therapeutics LLC | $148.74 | 2023-2025 | Zoladex, Quzyttir |
| Takeda Pharmaceuticals U.S.A., INC. | $137.80 | 2024-2025 | Alunbrig, Iclusig, Hyqvia |
| Eisai INC. | $134.29 | 2023-2025 | |
| Glaxosmithkline, LLC. | $133.84 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Gilead Sciences, INC. | $98.43 | 2023-2025 | |
| Celgene Corporation | $96.20 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Seagen INC. | $95.00 | 2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $93.37 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
| Legend Biotech USA INC. | $61.18 | 2025 | Carvykti |
| Rigel Pharmaceuticals, INC. | $58.72 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Genmab U.S., INC. | $57.65 | 2024 | Tivdak |
| Genentech USA, INC. | $56.34 | 2025 | Polivy, Itovebi |
| Puma Biotechnology, INC. | $45.36 | 2023-2024 | Nerlynx |
| Aveo Pharmaceuticals, INC. | $44.31 | 2023-2025 | Fotivda |
| Astellas Pharma US INC | $39.63 | 2025 | Vyloy |
| Sumitomo Pharma America, INC. | $39.30 | 2025 | Orgovyx |
| Genzyme Corporation | $37.39 | 2024-2025 | |
| Taiho Oncology, INC. | $36.30 | 2025 | |
| Stemline Therapeutics INC. | $33.28 | 2025 | Orserdu |
| Kite Pharma, INC. | $31.96 | 2025 | Yescarta |
| Coherus Oncology, INC. | $30.17 | 2025 | Loqtorzi |
| Ipsen Biopharmaceuticals, INC | $27.30 | 2023 | Onivyde |
| Iovance Biotherapeutics, INC. | $24.05 | 2025 | Amtagvi |
| Pharmacosmos Therapeutics INC. | $23.62 | 2025 | Monoferric |
| Syndax Pharmaceuticals, INC. | $23.41 | 2025 | |
| Geron Corporation | $22.48 | 2025 | Rytelo |
| Immunocore Limited | $22.23 | 2024 | Kimmtrak |
| Telix Pharmaceuticals | $18.57 | 2024 | Illuccix |
| Springworks Therapeutics, INC. | $17.58 | 2025 | Ogsiveo |
| Melinta Therapeutics, LLC | $17.53 | 2025 | Rezzayo |
| Exelixis INC. | $14.67 | 2024 | Cabometyx |
| Biocon Biologics INC | $13.61 | 2025 | Ogivri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halie Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.